{"protocolSection": {"identificationModule": {"nctId": "NCT00291655", "orgStudyIdInfo": {"id": "N01237"}, "secondaryIdInfos": [{"id": "EUDRACT NUMBER: 2006-000173-29"}], "organization": {"fullName": "UCB Pharma", "class": "INDUSTRY"}, "briefTitle": "Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).", "officialTitle": "A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam, for Patients Suffering From Epilepsy and Coming From the Study N01175 (NCT00175903)."}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-02-10", "studyFirstSubmitQcDate": "2006-02-10", "studyFirstPostDateStruct": {"date": "2006-02-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-25", "resultsFirstSubmitQcDate": "2009-10-09", "resultsFirstPostDateStruct": {"date": "2009-11-13", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-29", "lastUpdatePostDateStruct": {"date": "2015-05-18", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "UCB Pharma", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "For ethical reasons to give opportunity for adult subjects (\u226516 or 18 years) suffering from newly diagnosed epilepsy who completed the therapeutic confirmatory, open-label trial N01175 (NCT00175903) conducted with levetiracetam in monotherapy and who benefited from the treatment, to receive treatment with levetiracetam until the monotherapy indication for levetiracetam is granted in Europe.\n\nTo continue to assess safety of levetiracetam as per adverse event reporting and observation of weight changes."}, "conditionsModule": {"conditions": ["Epilepsy"], "keywords": ["NEWLY DIAGNOSED EPILEPSY", "LEVETIRACETAM", "KEPPRA", "N01175 (NCT00175903)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 130, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Levetiracetam (LEV)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Levetiracetam"]}], "interventions": [{"type": "DRUG", "name": "Levetiracetam", "description": "500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study", "armGroupLabels": ["Levetiracetam (LEV)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase", "description": "Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).", "timeFrame": "during open-label therapy phase of 18 months"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months", "timeFrame": "Start of open-label therapy (Baseline) to withdrawal or end of study after 18 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male/female adult subjects (\u2265 16 or 18 years)\n* Diagnosis of epilepsy (all types of seizures may be included)\n* Subjects who completed N01175 (NCT00175903) trial and benefited from levetiracetam monotherapy\n\nOther inclusion criteria may apply\n\nExclusion Criteria:\n\n* Subjects withdrawn from N01175 (NCT00175903) trial for any reason\n* Subjects who received treatment other than levetiracetam in N01175 (NCT00175903) trial\n* Subject requiring add-on antiepileptic treatment\n* Subjects from countries where levetiracetam is authorized for use as monotherapy in epilepsy treatment\n* Sexually active woman with childbearing potential who is not using a medically accepted birth control method", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "16 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "UCB Clinical Trial Call Center", "affiliation": "+1 877 822 9493 (UCB)", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Brugge", "country": "Belgium", "geoPoint": {"lat": 51.20892, "lon": 3.22424}}, {"city": "Edegem", "country": "Belgium", "geoPoint": {"lat": 51.15662, "lon": 4.44504}}, {"city": "Gent", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"city": "Haine St Paul", "country": "Belgium", "geoPoint": {"lat": 50.46185, "lon": 4.1767}}, {"city": "Jette", "country": "Belgium", "geoPoint": {"lat": 50.87309, "lon": 4.33419}}, {"city": "Kortrijk", "country": "Belgium", "geoPoint": {"lat": 50.82803, "lon": 3.26487}}, {"city": "Leuven", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"city": "Oostende", "country": "Belgium", "geoPoint": {"lat": 51.21551, "lon": 2.927}}, {"city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Varna", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"city": "Hus (helsinki)", "country": "Finland"}, {"city": "Kuopio", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"city": "Tampere", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"city": "Blaye", "country": "France", "geoPoint": {"lat": 45.13333, "lon": -0.66667}}, {"city": "Bordeaux", "country": "France", "geoPoint": {"lat": 44.84044, "lon": -0.5805}}, {"city": "Brest", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"city": "Carcassonne", "country": "France", "geoPoint": {"lat": 43.21667, "lon": 2.35}}, {"city": "Cherbourg", "country": "France", "geoPoint": {"lat": 49.63984, "lon": -1.61636}}, {"city": "Lille", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"city": "Lyon Cedex", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"city": "Nancy", "country": "France", "geoPoint": {"lat": 48.68439, "lon": 6.18496}}, {"city": "Rennes", "country": "France", "geoPoint": {"lat": 48.11198, "lon": -1.67429}}, {"city": "Saint Brieuc", "country": "France", "geoPoint": {"lat": 48.51513, "lon": -2.76838}}, {"city": "Saint Quentin", "country": "France", "geoPoint": {"lat": 49.84889, "lon": 3.28757}}, {"city": "TOULOUSE Cedex 04", "country": "France", "geoPoint": {"lat": 43.60426, "lon": 1.44367}}, {"city": "Valenciennes", "country": "France", "geoPoint": {"lat": 50.35, "lon": 3.53333}}, {"city": "Czestochowa", "country": "Poland", "geoPoint": {"lat": 50.79646, "lon": 19.12409}}, {"city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"city": "Olstyn", "country": "Poland"}, {"city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Biel", "country": "Switzerland", "geoPoint": {"lat": 47.13713, "lon": 7.24608}}, {"city": "Lausanne", "country": "Switzerland", "geoPoint": {"lat": 46.516, "lon": 6.63282}}, {"city": "St Gallen", "country": "Switzerland", "geoPoint": {"lat": 47.42391, "lon": 9.37477}}, {"city": "Zurich", "country": "Switzerland", "geoPoint": {"lat": 47.36667, "lon": 8.54999}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "FDA Safety Alerts and Recalls", "url": "http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Participants Flow describes all subjects treated at least once during open-label monotherapy with Levetiracetam.", "groups": [{"id": "FG000", "title": "Levetiracetam Open- Label Treatment", "description": "Open-label treatment with Levetiracetam 500 mg oral tablets in monotherapy, 1000 - 3000 mg/day bid over up to 18 months"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "130"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "115"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Levetiracetam Open- Label Treatment", "description": "Open-label treatment with Levetiracetam 500 mg oral tablets in monotherapy, 1000 - 3000 mg/day bid over up to 18 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "130"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.68", "spread": "18.35"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "58"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "72"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "France", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}, {"title": "Finland", "categories": [{"measurements": [{"groupId": "BG000", "value": "9"}]}]}, {"title": "Poland", "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}]}]}, {"title": "Belgium", "categories": [{"measurements": [{"groupId": "BG000", "value": "25"}]}]}, {"title": "Bulgaria", "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}]}]}, {"title": "Switzerland", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Assessment of Safety of Levetiracetam as Per Adverse Event (AE) Reporting in Open-label Therapy Phase", "description": "Summarization for occurrence of adverse events like number of subjects with any adverse events or drug related adverse events is provided (see categories).", "populationDescription": "Safety population that includes all subjects that have been treated once.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "during open-label therapy phase of 18 months", "groups": [{"id": "OG000", "title": "Levetiracetam Open- Label Treatment", "description": "Open-label treatment with Levetiracetam 500 mg oral tablets in monotherapy, 1000 - 3000 mg/day bid over up to 18 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "130"}]}], "classes": [{"title": "Subjects with at least one AE", "categories": [{"measurements": [{"groupId": "OG000", "value": "40"}]}]}, {"title": "Subjects with AEs leading to dose change", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}]}]}, {"title": "Subjects with AEs leading to trial discontinuation", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}, {"title": "Subjects with drug-related AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "16"}]}]}, {"title": "Subjects with AEs of severe intensity", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}]}]}, {"title": "Subjects with serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Subjects with study drug-related serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}, {"title": "Number of deaths", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight to Withdrawal or End of Study After 18 Months", "populationDescription": "Subjects with a discontinuation visit", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Start of open-label therapy (Baseline) to withdrawal or end of study after 18 months", "groups": [{"id": "OG000", "title": "Levetiracetam Open- Label Treatment", "description": "Open-label treatment with Levetiracetam 500 mg oral tablets in monotherapy, 1000 - 3000 mg/day bid over up to 18 months"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "79"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.71", "spread": "3.16"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Open-label treatment over 18 months", "eventGroups": [{"id": "EG000", "title": "Levetiracetam Open- Label Treatment", "description": "Open-label treatment with Levetiracetam 500 mg oral tablets in monotherapy, 1000 - 3000 mg/day bid over up to 18 months", "seriousNumAffected": 6, "seriousNumAtRisk": 130, "otherNumAffected": 10, "otherNumAtRisk": 130}], "seriousEvents": [{"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Hepatic cirrhosis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Grand mal convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Alcoholism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Tonsillitis", "organSystem": "Infections and infestations", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "medDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 130}]}], "otherEvents": [{"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 130}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 9.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 130}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "UCB has \\> 60 days but \\<= 180 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome."}, "pointOfContact": {"title": "UCB Clinical trial call center", "organization": "UCB Pharma", "phone": "+1 877 822 9493"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Austria", "Czech Republic", "Denmark", "Germany", "Greece", "Ireland", "Italy", "Netherlands", "Norway", "Russian Federation", "Slovakia", "Spain", "Sweden", "Turkey", "United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000004827", "term": "Epilepsy"}], "ancestors": [{"id": "D000001927", "term": "Brain Diseases"}, {"id": "D000002493", "term": "Central Nervous System Diseases"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M7983", "name": "Epilepsy", "asFound": "Epilepsy", "relevance": "HIGH"}, {"id": "M5204", "name": "Brain Diseases", "relevance": "LOW"}, {"id": "M5742", "name": "Central Nervous System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000077287", "term": "Levetiracetam"}], "ancestors": [{"id": "D000000927", "term": "Anticonvulsants"}, {"id": "D000018697", "term": "Nootropic Agents"}], "browseLeaves": [{"id": "M1741", "name": "Levetiracetam", "asFound": "Deliver", "relevance": "HIGH"}, {"id": "M4246", "name": "Anticonvulsants", "relevance": "LOW"}, {"id": "M20774", "name": "Nootropic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AntiConv", "name": "Anticonvulsants"}, {"abbrev": "NootAg", "name": "Nootropic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}